Tocilizumab (Actemra)

Actemra Cuts Steroid Needs Even in Nonresponders

Drug may still benefit patients in one respect when disease symptoms persist. Read more

Tocilizumab (Actemra) may have positive effects in patients not showing clinical responses by allowing reductions in corticosteroids doses, according to a five-center French study appearing online in Rheumatology.

Led by rheumatologist Clémentine Fortunet, MD, Dijon University Hospital, Dijon, France, the study found that corticosteroid doses could be significantly reduced after patients started on tocilizumab, with a trend toward greater reductions in patients not meeting criteria for a clinical response to the biologic drug./.../